碳酸酐酶IX靶向[68Ga]Ga-DPI-4452 PET/CT在肾细胞癌中的前瞻性多中心对比研究
该前瞻性多中心研究纳入68例肾细胞癌患者,比较[68Ga]Ga-DPI-4452 PET/CT与[18F]FDG PET/CT的诊断性能。在透明细胞肾细胞癌亚组中,[68Ga]Ga-DPI-4452的准确率显著更高(98.2% vs 76.8%,P=0.0034),病灶检出率更高(97.9% vs 47.1%),且SUVmax和肿瘤/本底比值均显著更优(均P<0.001)。
要点
- 在ccRCC亚组中,[68Ga]Ga-DPI-4452诊断准确率98.2%,显著高于FDG的76.8%
- ccRCC亚组中[68Ga]Ga-DPI-4452检出97.9%病灶,FDG仅47.1%
- ccRCC亚组中[68Ga]Ga-DPI-4452导致37.5%患者临床管理改变,FDG仅1.8%
核心结论
- 在透明细胞肾细胞癌中,[68Ga]Ga-DPI-4452 PET/CT较[18F]FDG PET/CT具有更优的病灶检出、肿瘤/本底对比度和诊断准确率,可能成为新的分子影像标准。
研究设计与样本
- 前瞻性多中心研究纳入68例肾细胞癌患者,涵盖初诊原发肿瘤、主动监测或系统治疗中及疑似复发转移者,两种PET/CT均在同一周内完成。
主要发现
- 总体诊断准确率[68Ga]Ga-DPI-4452为92.6%,[18F]FDG为80.9%(P=0.1435)。
- ccRCC亚组(n=56)准确率分别为98.2%和76.8%(P=0.0034)。
- [68Ga]Ga-DPI-4452检出全部病灶的90.9%(ccRCC中97.9%),[18F]FDG为56.7%(ccRCC中47.1%)。
- 中位SUVmax为19.7 vs 4.3,中位最大肿瘤/本底比为19.8 vs 2.1(均P<0.001)。
- ccRCC亚组中[68Ga]Ga-DPI-4452导致21例(37.5%)临床管理改变,[18F]FDG仅1例(1.8%),未观察到不良事件。
临床怎么用
- 在ccRCC患者中,[68Ga]Ga-DPI-4452 PET/CT可提高病灶检出和诊断准确率,并可能影响临床管理决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The objective of this study was to prospectively compare the diagnostic performance, lesion detection capability, and clinical staging impact of [68Ga]Ga-DPI-4452 PET/CT with that of [18F]FDG PET/CT in renal cell carcinoma (RCC) using a multicenter design. Methods: Sixty-eight patients with RCC were prospectively enrolled, including patients with newly diagnosed primary tumors, patients under active surveillance or ongoing systemic treatment, and patients with suspected recurrent or metastatic disease. Both PET/CT scans were performed within the same week. The primary endpoint was patient-based diagnostic accuracy; secondary endpoints included lesion detection rate, SUVmax, maximum tumor-to-background ratio, clinical management impact, and adverse events. Results: The median age was 59.5 y; 52 patients (76.5%) were men. Overall diagnostic accuracy was 92.6% for [68Ga]Ga-DPI-4452 PET/CT versus 80.9% for [18F]FDG PET/CT (P = 0.1435). In the clear cell RCC (ccRCC) subgroup (n = 56), accuracy was 98.2% versus 76.8%, respectively (P = 0.0034). [68Ga]Ga-DPI-4452 detected 90.9% of all lesions (97.9% in ccRCC), compared with 56.7% (47.1% in ccRCC) for [18F]FDG. Median SUVmax was 19.7 versus 4.3, and median of the maximum tumor-to-background ratio was 19.8 versus 2.1 for [68Ga]Ga-DPI-4452 versus [18F]FDG (both P < 0.001). In the ccRCC subgroup, [68Ga]Ga-DPI-4452 led to clinical management changes in 21 patients (37.5%), compared with 1 patient (1.8%) for [18F]FDG. No adverse events were observed. Conclusion: [68Ga]Ga-DPI-4452 PET/CT provides superior lesion detection, tumor-to-background contrast, and diagnostic accuracy compared with [18F]FDG PET/CT in ccRCC, reflecting direct visualization and targeting of the von Hippel-Lindau, hypoxia-inducible factor, and carbonic anhydrase IX axis. With its rapid pharmacokinetic profile and theranostic potential, [68Ga]Ga-DPI-4452 may represent a new molecular imaging standard in ccRCC.
引用
- Kömek H, Arslan E, Can C, et al. From Metabolism to Molecular Phenotype: Carbonic Anhydrase IX-Targeted [68Ga]Ga-DPI-4452 PET/CT in Renal Cell Carcinoma: A Prospective Multicenter Comparison with [18F]FDG PET/CT. J Nucl Med. 2026. PMID: 42754347. doi:10.2967/jnumed.126.273011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。